GSK1292263

Research use only, not for human use.

GSK1292263 is a novel potent, selective GPR119 agonist, elevates circulating glucose-dependent insulinotropic peptide.

GSK1292263 is a novel potent, selective GPR119 agonist, elevates circulating glucose-dependent insulinotropic peptide, GLP-1 and peptide tyrosine-tyrosine in nonclinical models of diabetes, with no effect on plasma glucose.Dyslipidemia Phase 2 Discontinued(In Vivo):GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats.

——

GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats. Animal Model:Male neonatal Streptozotocin (STZ)-induced SD rats (7 weeks of age)Dosage:30 mg/kg Administration:Orally given; once a day for 2 weeks Result:The AUC of plasma glucose (AUCPG) in the single treatment of the GSK1292263 group was numerically lower than that of the vehicle group, but the effect was modest.

GSK 1292263 | GSK-1292263

GPCR/G Protein

GPR119

GPR119

Cardiovascular Disease

Dyslipidemia

1032823-75-8

456.5578

C23H28N4O4S

>98% (HPLC)

DMSO: ≥ 30 mg/mL

O=S(C1=CC=C(C2=CC=C(OCC3CCN(C4=NC(C(C)C)=NO4)CC3)C=N2)C=C1)(C)=O

Pyridine, 5-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]methoxy]-2-[4-(methylsulfonyl)phenyl]-

(-20℃)

With Ice Pack

≥ 2 years